MNTA 2012-2014 News Flow
[Modified entry for FoB program.]
Lovenox
• 24-Jan-2012: Amphastar’s appeal of Lovenox preliminary injunction at the Court of Appeals for the Federal Circuit (Washington DC). Pleadings are due on 1/9/12.
• 25-Jan-2012: NVS reports 4Q12 sales of generic Lovenox. This will be the first quarterly number that shows the effect of Sanofi’s authorized generic.
• 4-Feb-2013: Start of NVS/MNTA’s patent-infringement lawsuit against Teva. (The trial date could be accelerated if this case were consolidated with MNTA’s suit against Amphastar.)
Copaxone
• Early 2012: Court ruling on Copaxone patent trial.
• Timing uncertain: FDA action on Copaxone ANDA.
Other programs
• 1Q12: IND filing for M402, MNTA’s proprietary heparin-based cancer drug, followed by the start of a phase-1 trial.
• Timing uncertain (probably late 2013 or 2014): Announcement of the identities of one or both of the first two FoB’s in MNTA’s partnership with BAX.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
